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Abstract
Gut immune components are severely compromised among persons with AIDS, which allows
increased translocation of bacterial lipopolysaccharides (LPS) into the systemic circulation. These
microbial LPS are reportedly increased in chronically HIV-infected individuals and findings have
correlated convincingly with measures of immune activation. Immune reconstitution inflammatory
syndrome (IRIS) is an adverse consequence of the restoration of pathogen-specific immune
responses in a subset of HIV-infected subjects with underlying latent infections during the initial
months of highly active antiretroviral treatment (HAART). Whether IRIS is the result of a response
to a high antigen burden, an excessive response by the recovering immune system, exacerbated
production of pro-inflammatory cytokines or a lack of immune regulation due to inability to
produce regulatory cytokines remains to be determined. We theorize that those who develop IRIS
have a high burden of proinflammatory cytokines produced also in response to systemic bacterial
LPS that nonspecifically act on latent mycobacterial antigens. We also hypothesize that subjects that
do not develop IRIS could have developed either tolerance (anergy) to persistent LPS/tubercle
antigens or could have normal FOXP3+ gene and that those with defective FOXP3+ gene or those
with enormous plasma LPS could be vulnerable to IRIS. The measure of microbial LPS, anti-LPS
antibodies and nonspecific plasma cytokines in subjects on HAART shall predict the role of these
components in IRIS.
Background
Immune reconstitution inflammatory syndrome (IRIS): An 
existing lacuna in HIV immunology?
IRIS is an adverse consequence of the restoration of path-
ogen-specific immune responses in HIV-infected patients
during the initial months of highly active antiretroviral
treatment (HAART) [1]. Even though IRIS is also closely
associated with certain other infectious (mycobacteria,
varicella zoster, herpesviruses, and cytomegalovirus) and
non-infectious (autoimmune) conditions [2-10], the
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morbidity associated with HIV/tuberculosis (TB) is more
important [1,11] as the crisis seem to be alarming in third-
world nations, where the proportion of HIV/TB IRIS is
reportedly high, ranging from 11% to 43% [12-15]. This
could be due to differences in cohort characteristics, case
definitions and differences in the mean time interval
between TB diagnosis and antiretroviral therapy (ART)
initiation. Data from resource-limited countries on TB-
IRIS is scarce; a rate of 8% was reported from India [1].
Immunology of IRIS in HIV/TB is deficient and HIV-spe-
cific T lymphocyte responses have repeatedly shown to be
defective [16]. To understand the immunopathogenesis of
IRIS it will be crucial to elucidate the intrinsic dynamics of
immune cells after initiation of HAART [17]. Preliminary
investigations have shown that an acute exacerbation of
mycobacteria-specific Th1 response after HIV infection
control by HAART causes IRIS in HIV/TB [17,18].
Does CD4+ T-cell depletion lead to a breach in gut 
immune cell integrity to initiate the proinflammatory 
cytokine saga?
In the context of an HIV infected subject with latent pul-
monary TB, progressing to AIDS stage of HIV disease, the
acute stage of the infection is characterized by eventual
depletion in the number of CD4+ T-cells, the key orches-
trator of all immune mechanisms in the body. Recent
research has re-examined the rate of immunopathologic
events in HIV disease, where the first few weeks is charac-
terized by massive viremia and depletion of ~50% mem-
ory CD4+ T-cell (CCR5+) population especially in the gut
[19-26]. Since the gut associated lymphoid tissue (GALT)
comprises ~60% of entire lymphoid organ system, rich in
memory cells, its depletion has a strong consequence on
the entire CD4+ T-cell population. Memory CD4+ T-cells
in the lamina propria is depleted principally by Fas-FasL-
mediated cell death [26]. In addition, productive HIV
infection is favored by an inflammatory environment,
because Th1 cytokines (IL-2, IL-12, TNF-α) increase NFkB
activation in T-cells, which drives HIV transcription. Early
breach in the gut mucosal integrity and epithelial micro-
environment [19-21,27-30] leads to increased transloca-
tion of luminal microbial products [20] because the gut is
thought to be the principal source of microbial products
(especially LPS) and because it has a massive bacterial
load compared to other anatomical sites [31-33]. Translo-
cation results in chronic inflammation via Toll-like recep-
tor (TLR-4) stimulation, resulting in cytokine and
chemokine release driving persistent T-cell activation and
(tat mediated) apoptosis via activation-induced cell
death (AICD) [21]. However, due to lack of sufficient
CD4+ T-cells, complex inflammatory mechanisms might
not be expected due to anergy.
HAART, immunological restoration and the inflammatory 
milieu: Who are the possible mediators?
Most of the subjects with HIV disease attend HIV testing
centers in India only after advanced clinical HIV disease
(AIDS) sets in and when their CD4+ T-cell counts are low
[1,11]. In spite of initiation of HAART, some experience a
'discordant response', whereby the HIV-1 RNA plasma
level is below the limit of detection but the CD4+ cell
count response is blunted. We propose that these individ-
uals with HIV/TB coinfection might not progress to clini-
cal IRIS owing to poor immune reconstitution despite
considerable virological recovery. As a consequence, a
substantial proportion of treated individuals show poor
CD4+ T-cell recovery [40]. This has also been correlated
with a lower nadir pretreatment CD4+ T-cell count, sug-
gestive of more extensive depletion of CD4+ T-cells in the
GALT during acute HIV infection, which may be refractory
to reconstitution with ART [19,41]. Initiation of HAART
allows 'partial' immune restoration [42], which however,
can result in the substantial proliferation and differentia-
tion of most of the immune components [43,44]. Due to
immune restoration, an inflammatory response against
infectious and non-infectious antigens (LPS) is mounted
leading to noticeable 'paradoxical worsening' [43-45],
with a shift toward a Th1 receptor profile, which increases
the levels of IFN-γ and IL-2 [46-51]. Therefore, persons
with latent TB or other systemic commensal antigens
(LPS) could lead to exaggerated inflammatory responses.
Studies also show that an inflammatory response is
required for the elimination of any gram-negative infec-
tion (i.e. LPS) [52]. HAART treatment (that enable 'partial'
immune reconstitution) considerably reduces circulating
LPS although total clearance may not be feasible for con-
siderable periods of time.
Bacterial LPS, the microbe-associated molecular patterns
(MAMP) of gram-negative bacteria are known potent acti-
vators of cells of inflammatory system. Plasma LPS levels
have been directly associated with the degree of intestinal
permeability following invasive gastrointestinal surgery
[34], inflammatory bowel disease (IBD) [35] and graft-
versus host disease (GVHD) [31,35-39]. Experimental SIV
infection of macaques resulted in raised circulating LPS
levels [21]. Recent studies have found significantly ele-
vated levels of plasma LPS in chronically HIV-infected
humans with progressive disease [21] and has correlated
convincingly with measures of innate and adaptive
immune activation. Besides, the study also has shown the
association between LPS and chronic in vivo stimulation
of monocytes, an association between raised plasma LPS;
and an association between reduction in plasma LPS and
CD4+ T-cell reconstitution with HAART [21]. Due to
abrupt increase in the numbers of CD4+ T-cells, the pat-
tern recognition receptors (PRR) induce signal transduc-
tion pathway molecules like NFkB, IL-1 receptor, TNFAIDS Research and Therapy 2007, 4:29 http://www.aidsrestherapy.com/content/4/1/29
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receptor, MAP kinase receptor etc. [53]. Cytokines such as
IL-1 can also stimulate the NFkB binding molecule to acti-
vate NFkB [54-56], which induces the expression of
cyclooxygenase-2 (COX-2), which consequently leads to
tissue inflammation at the site where latent TB antigens
are located. Interestingly, the expression of the COX-2-
encoding gene, believed to be responsible for the massive
production of prostaglandins at inflammatory sites, is
transcriptionally regulated by NFkB [54]. NFkB resides in
the cytoplasm and is bound to its inhibitor. Furthermore,
injurious and inflammatory stimuli, such as free radicals
present in the plasma of the immune deteriorated host
leads to NFkB release that subsequently moves into the
nucleus to activate the genes responsible for COX-2
expression.
Alternatively, effector T-cells of the Th1 subset activates
macrophages by CD154 – CD4+0 interactions and by
secreting IFN-γ. Th1 subsets produce the proinflammatory
cytokines, IL-2, IFN-γ, and TNF-α, and Th2 cells, the anti-
inflammatory cytokines, IL-4, 5, 6, 10, and 13. In addi-
tion, macrophages that have phagocytosed TB bacilli pro-
duce IL-12 that stimulates the differentiation of naïve
CD4+ T-cells to the Th1 subset, which again produces
IFN-γ on encountering macrophage-associated microbial
antigens; IL-12 also increases the amount of IFN-γ pro-
duced by these T-cells. In different T-cell mediated dis-
eases, tissue injury is caused by a delayed-type
hypersensitivity response mediated by CD4+ T-cells or by
lysis of host cells by CD8+ CTLs. Some studies suggest that
circulating IL-6 levels prior to HAART may be associated
with IRIS [53]. CD4+ T-cells may react against cell or tis-
sue antigens and secrete cytokines that induce local
inflammation and activate macrophages. The actual tissue
injury is caused by the macrophages and other inflamma-
tory cells. CD8+ T-cells specific for antigens on autologous
cells may directly kill these cells. Increased LPS-binding
protein (LBP) may also increase the host response and
potentiate injury. We hypothesize that the excessive pres-
ence of LPS in HIV/TB coinfected subjects accounts for the
progression of IRIS and those that have LPS in limited
concentrations may not. In studies in which normal
human subjects were treated with LPS intravenously,
there was a shift toward a Th2 response with increased
expression of IL-10, [57-59] and the pretreatment of
healthy human volunteers with IL-10 reduced the LPS-
induced increases in chemokines [60,61]. Data from stud-
ies in normal human volunteers suggest that LPS increase
the production of circulating IL-10, which would then
blunt the proinflammatory response to a second bacterial
challenge [60,61]. The Th2 shift in sepsis suggests that an
excess of anti-inflammatory cytokines may result in
impaired lung host response. We therefore hypothesize
that this situation could also lead to extensive multiplica-
tion of TB bacilli. A brief overview of the concept is illus-
trated in figure 1.
The likelihood of 'normal' FOXP3+ gene and endotoxin-
tolerance among IRIS non-developers – Why?
This 'paradoxical worsening' could also be attributable to
additional presence of defective FOXP3+ gene among IRIS
developers. Presence of defective FOXP3+ gene in T-cells
has been reported to confer increased risk of inflamma-
tory conditions in human beings in contrast to a normal
FOXP3+ gene. After an initial exposure to LPS, monocytes
and macrophages become refractory to subsequent LPS
challenge (endotoxin-tolerance) (57 – 61). This initially
was believed to be protective against septic shock. How-
ever, recent evidence suggests that endotoxin-tolerance
impairs the host response to a second bacterial challenge
[62,63]. The prolonged presence of TB antigens (and a
normal FOXP3+ gene) could also lead to anergy and poor
immune responses to TB antigens despite HAART. Mono-
cytes obtained from septic patients have functional defects
that include profound defects in IL-1, 6, and TNF-α pro-
duction; loss of HLA class II antigen expression; and
impaired antigen presentation [64-69]. In patients with
sepsis, monocytes from survivors showed normal
cytokine response following LPS stimulation [64]. A
potential mechanism whereby endotoxin-tolerance devel-
ops is a down-regulation of LPS receptors such as mem-
brane CD14 on macrophages [70]. The exposure of
monocytes and macrophages to the anti-inflammatory
cytokines, IL-10 and TGF-β, is a second mechanism that
may be responsible for the monocyte deactivation that
resembles endotoxin-tolerance [71]. Studies performed
with human alveolar macrophages exposed to IL-10 in
vitro show increased intracellular bacterial replication of
Legionella pneumophila, [72] and decreased production of
proinflammatory cytokines [73]. These suggest that mac-
rophages and monocytes in septic patients may develop a
phenotype similar to that observed in endotoxin-toler-
ance, which could result in an impaired response to lung
pathogens. The development of tolerance was hypothe-
sized to be beneficial by diminishing the proinflamma-
tory response in patients with sepsis. However, some data
suggest that the development of tolerance may worsen
clinical outcomes because monocytes and macrophages
may not respond adequately to a bacterial challenge
[62,65,74]. The CD14/TLR complex and associated sign-
aling pathways are essential for the recognition of LPS by
macrophages, and several studies suggest that down-regu-
lation of CD14/TLR complexes on macrophages is
responsible for the development of tolerance
[63,70,75,76]. However, the development of tolerance
does not correlate with down-regulation of LPS-binding
sites [77], suggesting the possible role of other mecha-
nisms including the disruption of CD14/TLR
signaling pathways [78] and the macrophage exposure toAIDS Research and Therapy 2007, 4:29 http://www.aidsrestherapy.com/content/4/1/29
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anti-inflammatory IL-10 [79]. Therefore, it is hypothe-
sized that subjects that do not progress to develop IRIS
(IRIS tolerant) despite HAART initiation could develop
tolerance (anergy) to persistent LPS/tubercle antigens.
Conclusion
It is hypothesized that proinflammatory cytokines pro-
duced excessively in response to systemic bacterial LPS
nonspecifically act on latent mycobacterial antigens lead-
ing to clinical deterioration and 'paradoxical worsening'
of inflammatory responses against both infectious (HIV/
TB) and non-infectious (LPS) microbial antigens. This
'paradoxical worsening' could also be attributable to addi-
tional presence of defective FOXP3+ gene among IRIS
developers. Subjects that do not progress to develop IRIS
(IRIS tolerant) despite HAART initiation could develop
One possible mechanism that illustrates the immunology of IRIS in a subject with HIV/TB coinfection Figure 1
One possible mechanism that illustrates the immunology of IRIS in a subject with HIV/TB coinfection. Compro-
mised gut immunity leads to increased translocation of luminal gram negative bacterial LPS into the systemic circulation. Initia-
tion of HAART in the subject leads to abrupt restoration of CD4+ T-cells and almost any pathogen-specific immune response. 
IRIS developers have a high burden of LPS and proinflammatory cytokines produced against LPS could result in an exaggerated, 
nonspecific attack on latent mycobacterial antigens that are presented in the local lymph nodes leading to localized inflamma-
tion. We also hypothesize that subjects that do not develop IRIS could have developed either tolerance (anergy) to persistent 
LPS and tubercle antigens or could have normal FOXP3+ gene (not shown) and that those with defective FOXP3+ gene or 
enormous plasma LPS could be vulnerable to IRIS (as demonstrated by researchers that defective FOXP3+ gene is associated 
with increased risk for inflammatory conditions). (Bold lines indicate the availability of clinical/experimental evidence and 
dashed lines indicate the possible mechanism).AIDS Research and Therapy 2007, 4:29 http://www.aidsrestherapy.com/content/4/1/29
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either tolerance (anergy) to persistently existing LPS and
tubercle antigens. Thus far, no single treatment option
exists against IRIS and depends on the underlying infec-
tious agent and its clinical presentation. However, since
the pathogenesis is an inflammatory one, systemic corti-
costeroids or non-steroidal anti-inflammatory drugs
(NSAIDS) may assuage the symptoms. Therefore, studies
must be attempted to assess the role of immunological
correlates and possible markers of IRIS needs to be evalu-
ated to better understand the mechanisms behind IRIS in
HIV/TB or other opportunistic coinfections, which would
largely facilitate the timely management of IRIS in HIV/
AIDS.
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